Next-generation anti-VEGF agents for diabetic macular oedema

© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists..

The treatment and outcomes of diabetic macular oedema (DMO) have improved with the introduction of intravitreal injections. However, real-world data reveal that the burden of DMO treatment causes large gaps in outcomes between randomized clinical trials and daily clinical practice. Long-lasting intravitreal drugs and devices for DMO might reduce this disparity by achieving optimal treatment due to more feasible injection regimens. In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:36

Enthalten in:

Eye (London, England) - 36(2022), 2 vom: 09. Feb., Seite 273-277

Sprache:

Englisch

Beteiligte Personen:

Iglicki, Matias [VerfasserIn]
González, David Pérez [VerfasserIn]
Loewenstein, Anat [VerfasserIn]
Zur, Dinah [VerfasserIn]

Links:

Volltext

Themen:

2S9ZZM9Q9V
Angiogenesis Inhibitors
Bevacizumab
Journal Article
Review
Vascular Endothelial Growth Factor A

Anmerkungen:

Date Completed 15.04.2022

Date Revised 02.02.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1038/s41433-021-01722-8

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM329177028